{
  "question_stem": {
    "en": "A 72-year-old man with a history of Parkinson disease comes to the office for follow-up. The patient has been taking carbidopa-levodopa since being diagnosed 5 years ago and has required increasing doses to control his symptoms. He is now taking the maximum dose but has experienced bothersome motor fluctuations for the past several months. The patient also reports worsening stiffness and difficulty moving between his scheduled doses; these symptoms improve after he takes the medication. Entacapone is added to his treatment regimen. This drug is most likely to improve this patient's symptoms through which of the following mechanisms?",
    "zh": "一名有帕金森病病史的 72 岁男性前来复诊。患者自 5 年前被诊断出患有帕金森病以来，一直在服用卡比多巴-左旋多巴，并且需要增加剂量来控制症状。他现在正在服用最大剂量，但在过去几个月里经历了恼人的运动波动。患者还报告了在预定剂量之间出现僵硬加重和活动困难；这些症状在服药后有所改善。他的治疗方案中增加了恩他卡朋。这种药物最有可能通过以下哪种机制改善患者的症状？"
  },
  "question": {
    "en": "This drug is most likely to improve this patient's symptoms through which of the following mechanisms?",
    "zh": "这种药物最有可能通过以下哪种机制改善患者的症状？"
  },
  "options": {
    "A": {
      "en": "Decreasing peripheral levodopa degradation",
      "zh": "减少外周左旋多巴降解"
    },
    "B": {
      "en": "Directly stimulating dopamine receptors",
      "zh": "直接刺激多巴胺受体"
    },
    "C": {
      "en": "Enhancing the effect of endogenous dopamine",
      "zh": "增强内源性多巴胺的作用"
    },
    "D": {
      "en": "Inhibiting central muscarinic receptors",
      "zh": "抑制中枢毒蕈碱受体"
    },
    "E": {
      "en": "Inhibiting centrally active acetylcholinesterase",
      "zh": "抑制中枢活性乙酰胆碱酯酶"
    }
  },
  "correct_answer": "A",
  "explanation": {
    "en": "Parkinson disease is caused by degeneration of the dopaminergic neurons in the substantia nigra, leading to a progressive deficiency of dopamine in the brain. Direct dopamine replacement is impossible because dopamine cannot cross the blood-brain barrier, so levodopa (ie, L-DOPA), the immediate precursor of dopamine, is used. Once levodopa crosses the BBB, it is taken up by nigrostriatal neurons and converted to therapeutic dopamine in the brain.\n\nLevodopa is rapidly metabolized in the peripheral tissues to dopamine (via aromatic D-amino acid [DOPA] decarboxylase) and 3-O-methyldopa (via catechol O-methyltransferase [COMT]). Therefore, only a small percentage of levodopa reaches the brain. Both COMT inhibitors (eg, entacapone, tolcapone) and DOPA decarboxylase inhibitors (eg, carbidopa) decrease peripheral levodopa degradation and increase the amount of levodopa available to cross the blood-brain barrier.\n\nPatients are nearly always prescribed carbidopa with levodopa. The progression of Parkinson disease leads to an increasingly narrow therapeutic window, as seen in this patient with bothersome \"wearing off\" periods. In these patients, entacapone can be added to further increase the bioavailability of levodopa, produce more stable levodopa plasma concentrations, and prolong the therapeutic effect of each dose.\n\n(Choice B) Dopamine agonists (eg, pramipexole, bromocriptine) directly activate dopamine receptors in the brain without the need for metabolism to the active form (unlike levodopa). Entacapone has no direct effect on dopamine receptors and does not cross the blood-brain barrier.\n\n(Choice C) Amantadine enhances the effect of endogenous dopamine by increasing dopamine release and inhibiting its reuptake. It is also thought to cause anticholinergic effects (reduces tremor), as well as antagonism of N-methyl D-aspartate receptors (reduces glutamate-induced neurotoxicity).\n\n(Choices D and E) The dopamine insufficiency of Parkinson disease upsets the normal balance between dopamine and acetylcholine in the basal ganglia, resulting in cholinergic hypersensitivity. Anticholinergic medications (eg, trihexyphenidyl) counteract this effect by inhibiting central muscarinic receptors. Acetylcholinesterase inhibitors (eg, donepezil, rivastigmine) would increase the amount of acetylcholine in the CNS, which could worsen symptoms of Parkinson disease.\n\nEducational objective:\nParkinson disease is typically treated with levodopa (immediate precursor of dopamine), which crosses the blood-brain barrier. Levodopa is administered with DOPA decarboxylase inhibitors (eg, carbidopa) and sometimes catechol O-methyltransferase inhibitors (eg, entacapone) to reduce the peripheral metabolism of levodopa, resulting in increased levodopa bioavailability within the brain.",
    "zh": "帕金森病是由黑质多巴胺能神经元的变性引起的，导致大脑中多巴胺进行性缺乏。直接补充多巴胺是不可能的，因为多巴胺不能穿过血脑屏障，因此使用左旋多巴（即 L-DOPA），多巴胺的直接前体。一旦左旋多巴穿过血脑屏障，它会被黑质纹状体神经元摄取，并在大脑中转化为治疗性多巴胺。\n\n左旋多巴在外周组织中迅速代谢为多巴胺（通过芳香族 D-氨基酸 [DOPA] 脱羧酶）和 3-O-甲基多巴（通过儿茶酚-O-甲基转移酶 [COMT]）。因此，只有一小部分左旋多巴到达大脑。COMT 抑制剂（例如，恩他卡朋、托卡朋）和 DOPA 脱羧酶抑制剂（例如，卡比多巴）都可以减少外周左旋多巴的降解，并增加可穿过血脑屏障的左旋多巴量。\n\n患者几乎总是被处方卡比多巴联合左旋多巴。帕金森病的进展导致治疗窗口越来越窄，如本患者出现烦人的“疗效减退”期。在这些患者中，可以添加恩他卡朋以进一步增加左旋多巴的生物利用度，产生更稳定的左旋多巴血浆浓度，并延长每剂的治疗效果。\n\n(选项 B) 多巴胺激动剂（例如，普拉克索、溴隐亭）直接激活大脑中的多巴胺受体，而无需代谢成活性形式（与左旋多巴不同）。恩他卡朋对多巴胺受体没有直接影响，也不会穿过血脑屏障。\n\n(选项 C) 金刚烷胺通过增加多巴胺释放并抑制其再摄取来增强内源性多巴胺的作用。它也被认为会引起抗胆碱能作用（减少震颤），以及对 N-甲基-D-天冬氨酸受体（减少谷氨酸引起的神经毒性）的拮抗作用。\n\n(选项 D 和 E) 帕金森病的多巴胺不足扰乱了基底神经节中多巴胺和乙酰胆碱之间的正常平衡，导致胆碱能高敏感性。抗胆碱能药物（例如，苯海索）通过抑制中枢毒蕈碱受体来抵消这种影响。乙酰胆碱酯酶抑制剂（例如，多奈哌齐、利伐斯的明）会增加中枢神经系统中乙酰胆碱的量，这可能会加重帕金森病的症状。\n\n教学目标：\n帕金森病通常用左旋多巴（多巴胺的直接前体）治疗，左旋多巴可以穿过血脑屏障。左旋多巴与 DOPA 脱羧酶抑制剂（例如，卡比多巴），有时与儿茶酚-O-甲基转移酶抑制剂（例如，恩他卡朋）一起给药，以减少左旋多巴的外周代谢，从而增加大脑内的左旋多巴生物利用度。"
  },
  "summary": {
    "en": "This question tests the understanding of the mechanism of action of entacapone in the management of Parkinson disease, specifically its role in improving levodopa's efficacy by affecting its peripheral metabolism.\n\nThe approach to solving this question involves identifying the patient's symptoms as characteristic of Parkinson disease \"wearing off\" phenomena and understanding how entacapone, a COMT inhibitor, addresses this by increasing levodopa's bioavailability to the brain.",
    "zh": "这个问题考察对恩他卡朋在帕金森病管理中的作用机制的理解，特别是它通过影响左旋多巴的外周代谢来提高其疗效的作用。\n\n解决这个问题的方法包括将患者的症状识别为帕金森病“疗效减退”现象的特征，并了解恩他卡朋（一种 COMT 抑制剂）如何通过增加左旋多巴的脑内生物利用度来解决这个问题。"
  },
  "tags": "Parkinson disease; Levodopa; Entacapone; COMT inhibitor; Peripheral metabolism; Dopamine; Motor fluctuations; Pharmacology; Neurology",
  "category": "Neuro",
  "question_id": "265",
  "has_exhibits": true,
  "exhibit_count": 3,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg",
    "image3.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Neuro 24\\265",
  "extracted_at": "2025-11-05T19:39:55.394676",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 2,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:40:18.842523",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}